Videos

Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.

Roger Li, MD, addresses the open questions surrounding adjuvant therapy after cystectomy, the urologist's role in recognizing treatment-related toxicities, and why multidisciplinary referral is the change most likely to deliver the full benefit of perioperative therapy.

Roger Li, MD, explains why patients with MIBC fall away between TURBT and a medical oncology visit, how strong urologist–oncologist relationships speed the start of neoadjuvant therapy, and how newer non-cisplatin regimens are changing referral patterns and surgical timing.

Roger Li, MD, reviews how the NIAGARA, KEYNOTE-905, KEYNOTE-B15, and VOLGA trials are moving perioperative care for muscle-invasive bladder cancer beyond cisplatin-based chemotherapy and why the data should change which patients urologists refer for neoadjuvant therapy.

Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.

Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,

Explore how very high-risk localized prostate cancer is defined and treated, plus why PSMA PET findings shouldn’t automatically rule out curative therapy.

The 2026 LUGPA Annual Meeting will tackle policy, artificial intelligence, and practice growth, according to Benjamin H. Lowentritt, MD, FACS.

Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.

Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.

Neoadjuvant-only enfortumab vedotin in VOLGA may spare neuropathy, according to Alexandra Drakaki, MD, PhD; Guru P. Sonpavde, MD, urged caution.

Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.

Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.

Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.

Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.

Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.

Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.

Selecting candidates for radioligand therapy requires more than a positive PSMA scan, and the panel details how tracer avidity, disease volume, and sequencing with hormonal therapy affect outcomes.

A high-risk, newly diagnosed patient's PSMA PET results reshape surgical planning, nerve-sparing decisions, and the choice between surgery and radiation for definitive local therapy.

Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.

Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.

Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.

Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.

Delayed diagnosis and skipped nodal staging worsen penile cancer outcomes, according to Luis G. Medina, MD.

Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.

Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.

Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.

A rising PSA after treatment discontinuation prompts a PSMA PET that reveals a solitary rib lesion, testing how much confidence clinicians place in a single indeterminate finding.

Adoption of PSMA PET still varies by practice setting, and the panel discusses how visualized disease reshapes conversations with patients accustomed to tracking PSA values alone.

Daniel Spratt, MD, outlines the validation standards urologists should expect before adopting AI-based tools, where AI-driven digital pathology is headed, and his key takeaway from the benchmarking data.